iA Global Asset Management Inc. Increases Holdings in Zoetis Inc. $ZTS

iA Global Asset Management Inc. grew its stake in Zoetis Inc. (NYSE:ZTS) by 798.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,327 shares of the company’s stock after acquiring an additional 42,059 shares during the quarter. iA Global Asset Management Inc.’s holdings in Zoetis were worth $5,595,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. RFG Advisory LLC increased its stake in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership lifted its stake in shares of Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after buying an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. grew its holdings in shares of Zoetis by 2.4% during the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after buying an additional 85 shares during the last quarter. Quest 10 Wealth Builders Inc. grew its holdings in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after buying an additional 86 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. increased its position in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.9%

NYSE:ZTS opened at $72.48 on Thursday. The company has a market cap of $30.39 billion, a PE ratio of 12.02, a price-to-earnings-growth ratio of 1.12 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a 50 day simple moving average of $85.77 and a two-hundred day simple moving average of $109.95. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $161.77.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts forecast that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s dividend payout ratio is currently 35.16%.

Insiders Place Their Bets

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZTS shares. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Stifel Nicolaus reduced their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $126.92.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
• Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
• Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
• Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
• Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
• Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.